• WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
    • Partner
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS
  • WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
    • Partner
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS

Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.

Science 21. November 2022
ShareTwitterFacebookXingLinkedin
First published in Expert Opinion on Pharmacotherapy on 2014 Jun.Expert Opin Pharmacother. 2014 Jun;15(9):1299-313. doi: 10.1517/14656566.2014.920009 Authors: Forst T, Bramlage...
Read Article

Glycemic control and cardiovascular benefit: What do we know today?

Science 10. November 2022
ShareTwitterFacebookXingLinkedin
First published in Deutsche Medizinische Wochenschrift on 2010 Feb.Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. doi: 10.1055/s-0029-1244853.  Authors: Hanefeld M, Schönauer M,...
Read Article

High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone.

Science 10. November 2022
ShareTwitterFacebookXingLinkedin
First published in Journal of Diabetes Science and Technology on 2010 May.J Diabetes Sci Technol. 2010 May 1;4(3):706-16 Authors: Pfützner...
Read Article

Review of approved pioglitazone combinations for type 2 diabetes.

Science 10. November 2022
ShareTwitterFacebookXingLinkedin
First published in Expert Opinion on Pharmacotherapy on 2011 Jul.Expert Opin Pharmacother. 2011 Jul;12(10):1571-84. doi: 10.1517/14656566.2011.567266. Authors: Forst T, Hanefeld...
Read Article

Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.

Science 10. November 2022
ShareTwitterFacebookXingLinkedin
First published in Journal of Diabetes Science and Technology on 2011 May.J Diabetes Sci Technol. 2011 May 1;5(3):784-93 Authors: Pfützner...
Read Article

Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index?

Science 10. November 2022
ShareTwitterFacebookXingLinkedin
First published in Neuropsychiatric Disease and Treatment on 2011Neuropsychiatr Dis Treat. 2011;7:351-6. doi: 10.2147/NDT.S18455. Authors: Engel A, Helfrich J, Manderscheid...
Read Article

Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.

Science 10. November 2022
ShareTwitterFacebookXingLinkedin
First published in Journal of Diabetes Science and Technology on 2011 Jul.J Diabetes Sci Technol. 2011 Jul 1;5(4):989-98 Authors: Pfützner...
Read Article
QUICK LINKS
  • WE ARE
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • MANAGEMENT
  • EARLY PHASE
    • First-in-human
    • Cardiac safety
    • Infusion & injection
    • Inhalation
    • Pharmacology
    • Interaction
    • Consultancy
    • Medical Writing
    • Data Management
.
  • PATIENT TRIALS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
  • WORK WITH US
EXPERTISE
  • Consultancy
  • Medical Writing
  • Early Phase
FACILITIES
  • Berlin
  • Kiel
  • Mannheim
  • Wuppertal
FÜR PROBANDEN
  • ÜBER STUDIEN
  • AN STUDIEN TEILNEHMEN
  • www.probandeninfo.de
LEGAL
  • PRIVACY
  • IMPRINT
  • DISCLAIMER
  • —
  • Career
    • CURRENT JOB
    • OPPORTUNITIES
Copyright © 2023 CRS. Experts. Early Phase. All rights reserved.